Evidence map›Paper›PMID 42750201›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Granzyme B PET Imaging Reveals Lgmn

Dongliang Wang, Wenqin Luo, Qiufang Liu, Wenxuan Tang, Bin Zhu, Jiwei Chen, Qian Zhou, Shuang Tang, Xiaoping Xu, Shaoli Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dongliang Wang *Department of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Wenqin Luo *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Qiufang Liu *Department of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Wenxuan TangDepartment of Digestive Diseases and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Bin ZhuDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.ORCID https://orcid.org/0009-0004-4503-9782
Jiwei ChenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-6550-331X
Qian ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-1471-6651
Shuang TangDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-3501-7836
Xiaoping XuDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.
Shaoli SongDepartment of Nuclear Medicine, Shanghai Cancer Center, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-2544-7522

Funding

China Postdoctoral Science Foundation 2025M772252Construction Project of Shanghai Key Laboratory of Molecular Imaging 18DZ2260400National Natural Science Foundation of China 12275057National Natural Science Foundation of China 82272035National Natural Science Foundation of China 82502397National Natural Science Foundation of China U23A20465Shanghai Anticancer Association EYAS PROJECT SACA-CY24B10
6 · The paper itself

Abstract

Determining optimal therapies for EGFR-mutant NSCLC after tyrosine kinase inhibitor (TKI) resistance remains challenging. Immune checkpoint inhibitors (ICIs) show limited efficacy, but some patients regain immunotherapy sensitivity post-TKI. Non-invasive monitoring to identify responders and understand persistent immune tolerance is needed. In this study, we prospectively evaluated a novel granzyme B-targeted PET radiotracer,

Indexed as

68Ga‐GZB PET/CT imagingEGFR‐TKIextracellular vesiclesimmunotherapyLgmn+ macrophagesnon‐small cell lung cancer

Identifiers

PMID42750201
PMCPMC13583114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.